Sanctuary Advisors LLC Acquires Shares of 31,040 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Sanctuary Advisors LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 31,040 shares of the biopharmaceutical company's stock, valued at approximately $667,000.

Other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP bought a new stake in Catalyst Pharmaceuticals in the third quarter valued at approximately $1,185,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at $258,000. Integral Health Asset Management LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at $4,260,000. GSA Capital Partners LLP acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth $625,000. Finally, Capstone Investment Advisors LLC bought a new position in Catalyst Pharmaceuticals during the third quarter worth about $708,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the completion of the transaction, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Molly Harper sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 79,500 shares of company stock worth $1,754,140. Insiders own 11.00% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on CPRX. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. StockNews.com cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Finally, Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $31.14.

Catalyst Pharmaceuticals Stock Up 0.1 %

Shares of CPRX stock traded up $0.02 during trading on Wednesday, reaching $21.62. The company's stock had a trading volume of 247,349 shares, compared to its average volume of 1,163,915. Catalyst Pharmaceuticals, Inc. has a one year low of $13.12 and a one year high of $24.27. The business has a fifty day moving average price of $21.80 and a 200-day moving average price of $19.46. The company has a market cap of $2.58 billion, a price-to-earnings ratio of 18.32, a price-to-earnings-growth ratio of 3.35 and a beta of 0.75.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.